References
- GuerraSAsthma and chronic obstructive pulmonary diseaseCurr Opin Allergy Clin Immunol20099540941619638929
- PauwelsRABuistASCalverleyPMAJenkinsCRHurdSSGOLD Scientific ommitteeGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop SummaryAm J Respir Crit Care Med200116351256127611316667
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Updated 2013. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdfAccessed February 17, 2015
- BoydGMoriceAHPounsfordJCSiebertMPeslisNCrawfordCAn evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)Eur Respir J19971048158219150318
- TashkinDPFabbriLMLong-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agentsRespir Res20101114921034447
- RodrigoGJNeffenHComparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: a systematic reviewChest201214251104111022383666
- ToyELBeaulieuNUMcHaleJMTreatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costsRespir Med2011105343544120880687
- BouyssouTHoenkeCRudolfKDiscovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacyBioorg Med Chem Lett20102041410141420096576
- CazzolaMMateraMGLötvallJUltra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary diseaseExpert Opin Investig Drugs2005147775783
- Maleki-YazdiMRBeckEHamiltonALKorduckiLKokerPFogartyCA randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary diseaseRespir Med2015109559660525829298
- MillerMRHankinsonJBrusascoVStandardisation of spirometryEur Respir J200526231933816055882
- CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
- van NoordJASmeetsJJDrenthBM24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPDPulm Pharmacol Ther201124666667221839850
- DerendorfHNaveRDrollmannACerasoliFWurstWRelevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthmaEur Respir J20062851042105017074919
- KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
- FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
- FeldmanGJBernsteinJAHamiltonANivensMCKorduckiLLaForceCThe 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studiesSpringerplus2014341925187881
- LangePAumannJ-LHamiltonATetzlaffKTingNDeromEThe 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary diseaseJ Pulm Respir Med20144196
- ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
- Breekveldt-PostmaNSKoerselmanJErkensJALammersJ-WJHeringsRMCEnhanced persistence with tiotropium compared with other respiratory drugs in COPDRespir Med200710171398140517368011